The assessment of IDH mutations, predominantly IDH1 codon 132 and IDH2 codon 172 missense mutations, was recently incorporated into the updated 2016 WHO classification of CNS tumors [17]. This evidence concerns the gene IDH2 and central nervous system neoplasm.